Enterococci are gram-positive bacteria that normally colonize the intestinal tracts of humans and animals, where they usually live as harmless commensals. Yet two species in particular, Enterococcus faecalis and Enterococcus faecium, are among the most important causes of opportunistic and healthcare-associated infections. Enterococcus faecium is notorious for its capacity to acquire resistance to penicillins and, increasingly, to glycopeptides such as vancomycin, an antibiotic class introduced in 1955 that kills bacteria by binding to peptidoglycan precursors and blocking cell wall synthesis. Vancomycin-resistant enterococci were first described more than two decades after the drug’s introduction, and among resistant E. faecium isolates the vanB genotype has become the most prevalent in several European countries. VanB-type resistance is known for phenotypic variability, meaning that laboratory phenotype does not always reliably reflect the underlying resistance genes, a property that has now proven consequential in a dramatic way.

The public health stakes are considerable. The World Health Organization’s 2024 Bacterial Priority Pathogens List classifies vancomycin-resistant E. faecium as a high-priority pathogen, and according to the European Centre for Disease Prevention and Control the mean vancomycin resistance rate among European E. faecium isolates stands at roughly 20 percent. Austria had long reported comparatively low figures, with the national action program on antibiotic resistance documenting a resistance rate of just 3 percent among invasive isolates in 2023. That picture changed abruptly. After years without any invasive vancomycin-resistant E. faecium infections, the diagnostic laboratory serving Graz and the wider region observed the resistance rate among E. faecium-positive blood cultures climb to 6 percent in 2024 and then to 20 percent in the first half of 2025. By June 2025, thirty-one resistant isolates had been collected, and virtually all could be attributed to a single previously unreported lineage, ST117/CT7799.

The outbreak’s first signal appeared in February 2024, when automated VITEK2 susceptibility testing flagged vancomycin resistance in a clinical E. faecium isolate even though disk diffusion, gradient testing, and broth microdilution all failed to confirm it under routine conditions. When the laboratory reorganized its workflow to route all enterococcal isolates through automated testing and systematically re-examined results, five further isolates with the same distinctive phenotype emerged within months. All came from specimens obtained for genuine infection diagnostics rather than screening, and every case was confirmed as vanB-type resistance by molecular PCR. Retrospective review of raw instrument data found no evidence of this phenotype in the laboratory’s records before 2024, strongly suggesting a genuinely new arrival. Early cases clustered around invasive procedures performed at a single hospital, and a second transmission chain later surfaced among urology patients who had undergone double-J catheterization in an operating room shared with surgeons. Notably, environmental surface sampling by the hospital infection control team failed to locate the organism, and nearly all affected patients had either been hospitalized for at least four days or had recent inpatient care history with the same provider.

To characterize the outbreak, the team subjected twenty non-duplicate isolates to whole genome sequencing using both Illumina short-read and Oxford Nanopore long-read platforms, achieving highly concordant results between technologies. Core genome multilocus sequence typing based on 1,423 loci revealed a strikingly homogeneous cluster: even isolates sampled sixteen months apart differed by no more than six alleles, far below the cluster threshold of three alleles used for assignment once the clonal relationship was established. The nearest local control strain, isolated at the same site during the same period, differed by 159 alleles, and the closest reference strain from the Robert Koch Institute collection differed by 142 alleles. Searches of the cross-national surveillance platform MiGenomeSurv showed the next closest relative still 76 alleles away, confirming that CT7799 represents an entirely novel lineage. The clone was provisionally named VREfmstyr, after Styria, the Austrian federal state where it was first isolated.

Genomic analysis also illuminated the genetic architecture of resistance. All outbreak isolates carried a complete copy of the transposon Tn1549, the mobile element responsible for vanB-mediated vancomycin resistance, inserted into the chromosome. Long-read assemblies proved essential: short-read assemblies fragmented the transposon across three contigs, obscuring its structure, whereas long reads revealed three matching blocks separated by two intervening regions of 1,494 and 1,417 base pairs containing insertion sequence elements, including an ISL3-like transposase of the ISEfa11 family and an IS3-like ISEnfa3-family transposase alongside a helix-turn-helix domain protein. An additional IS91 transposase was found inserted in a YodL domain protein upstream of the vanB gene cluster. All seven vancomycin resistance genes, vanB, vanY-B, vanW-B, vanH-B, vanX-B, vanR-B, and vanS-B, were identical across every outbreak isolate, underscoring the clone’s remarkable genetic stability despite months of circulation. Based on the classification scheme of the Norwegian VRE study group, the vanB cassette appears to be a hybrid between variants typically associated with different sequence types, hinting at a recombination event in the strain’s recent history.

The true significance of the study, however, lies in its systematic evaluation of diagnostic methods, and the results are sobering. Broth microdilution, the reference standard for antimicrobial susceptibility testing, correctly identified only 16 of 31 isolates, or 52 percent, as vancomycin resistant when read after the standard 24 hours of incubation, even though all control strains behaved as expected. Extending incubation to 48 hours eventually pushed minimum inhibitory concentrations above the susceptibility breakpoint for all isolates, but the growth around concentrations of 2 milligrams per liter and above was so sparse that even trained personnel could easily overlook it. Gradient testing from two different manufacturers failed to detect resistance in every single case at 24 hours, and disk diffusion was equally deceptive: all isolates produced inhibition zone diameters clearly wider than the 12-millimeter resistance threshold, and the zone edges lacked the fuzzy appearance that typically signals vancomycin resistance. Only VITEK2 automated testing, which correctly flagged all 31 isolates under routine settings, proved reliable, a finding that diverges from earlier studies reporting only 81 percent sensitivity for low-MIC resistant strains and possibly reflecting improvements in newer test cards and software.

Screening carried a similar message of failure. When seven representative isolates were plated on kanamycin-vancomycin agar and four commercially available chromogenic VRE screening media, three of the four commercial agars yielded no growth at all after 24 hours, and the sole medium showing some activity was only weakly positive for four isolates and negative for the remaining three. Prolonging incubation to 48 and even 72 hours improved results only marginally and inconsistently across manufacturers, while the outbreak strain failed entirely to grow on kanamycin-vancomycin agar. These findings matter because VRE often constitutes only a small fraction of the intestinal enterococcal population, making selective screening media indispensable for controlling transmission, and because prior research has already shown that sensitivity drops sharply for strains with vancomycin minimum inhibitory concentrations below 16 milligrams per liter. Only CHROMagar VRE proved dependable after standard incubation, and even that required confirming results under the study’s specific conditions.

Intriguingly, when a representative isolate was exposed to vancomycin on a gradient strip for more than 100 hours, single colonies eventually grew within the inhibition zone, and after two passages the derivative consistently displayed a minimum inhibitory concentration of at least 32 milligrams per liter. Sequencing revealed that this resistant derivative carried a single nucleotide substitution in the vanS-B gene, the sensor kinase that regulates the vancomycin resistance operon, causing an amino acid change from serine to arginine at position 243. This observation suggests that the outbreak clone’s occult phenotype stems from a regulatory mutation or arrangement that dampens resistance expression, and that vancomycin pressure can select for compensatory variants restoring full resistance. The authors caution, however, that whether the insertion elements or the specific allele differences in vanR-B, vanY-B, and vanW-B are causally responsible for the difficult-to-detect phenotype remains an open question demanding further investigation.

The implications reach well beyond Styria. Because many diagnostic laboratories worldwide rely on 24-hour disk diffusion zone readings to determine vancomycin susceptibility, a strain with this phenotype could spread through hospitals without triggering any alarm, quietly colonizing patients and contaminating environments while appearing fully susceptible on paper. The research team recommends that laboratories verify the adequacy of their screening media and incubation times, and adapt their susceptibility testing protocols by prolonging incubation, adding molecular vanB PCR testing, or employing automated VITEK2 analysis. Given the clone’s demonstrated epidemic potential, its absence from all prior surveillance databases, and the growing proportion of invasive infections it now accounts for in the region, surveillance studies will be essential to determine whether ST117/CT7799 remains a local phenomenon or whether laboratories across Europe and beyond must urgently reassess whether their diagnostic procedures can catch a superbug designed, by evolutionary accident, to stay invisible.

Subject of Research: Emergence and diagnostic challenges of a novel vancomycin-resistant Enterococcus faecium clone (ST117/CT7799) in Austria

Article Title: Emergence of a Novel, Phenotypically Difficult‐to‐Detect Vancomycin‐Resistant Enterococcus faecium Clone (ST117/CT7799)

Article References: Forstner, P., Uitz, C., Dabernig‐Heinz, J., Wagner, G. E., Bender, J., Fischer, M., Siebenhofer, D., Werner, G., Busche, T., Klages, L. J., Rückert‐Reed, C., Steinmetz, I., & Dichtl, K. (2026). Emergence of a Novel, Phenotypically Difficult‐to‐Detect Vancomycin‐Resistant Enterococcus faecium Clone (ST117/CT7799). MicrobiologyOpen, 15(5), Article e70393. https://doi.org/10.1002/mbo3.70393

Image Credits: AI Generated

DOI: 10.1002/mbo3.70393

Keywords: vancomycin-resistant Enterococcus faecium, VRE, ST117/CT7799, hospital outbreak, antimicrobial resistance, vanB operon, Tn1549 transposon, whole genome sequencing, diagnostics, Austria, infection control, cgMLST

Hospital-acquired pneumonia (HAP) remains a significant concern in inpatient care worldwide, with NV-HAP representing a subtype occurring in patients who are not on mechanical ventilation yet develop pneumonia more than 48 hours after hospital admission. Despite sharing the clinical severity and consequences of ventilator-associated pneumonia (VAP), NV-HAP has historically been underresearched. This new trial bridges critical knowledge gaps by rigorously evaluating a simple yet effective intervention across three hospitals in Australia, resulting in data that could reshape hospital infection prevention practices globally.

The Hospital Acquired Pneumonia Prevention (HAPPEN) study enrolled a total of 8,870 patients across nine wards, employing a stepped-wedge cluster design. This methodology allowed a phased introduction of the intervention every three months in each ward over a 12-month period, culminating in August 2025. Its large sample size and pragmatic design distinguish it as the largest and most definitive randomized controlled trial targeting NV-HAP prevention through oral hygiene optimization conducted within acute care facilities.

The intervention was multifaceted, targeting both patients and healthcare providers. On admission, patients received oral care kits containing a toothbrush, toothpaste, and educational materials, supplemented by access to online resources emphasizing the importance of oral hygiene. Concurrently, healthcare workers received onsite training and practical support aimed at boosting oral care delivery standards. This comprehensive approach was designed not only to facilitate the practical execution of oral hygiene but also to address behavioral and systemic barriers identified in previous qualitative studies.

Implementation of the program yielded a staggering fourfold increase in the proportion of hospital patients receiving oral care—from a baseline of 15.9% up to 61.5% during the intervention phase. Audits further revealed an average frequency of oral care provision at approximately 1.5 times per day, reflecting consistent patient engagement and staff adherence to the new protocols. This marked improvement in oral hygiene practices set the stage for tangible clinical outcomes.

Most compelling was the dramatic decrease in NV-HAP incidence rates associated with the intervention. The rate fell from 1.00 to 0.41 cases per 100 admission days at risk, culminating in an overall risk reduction of about 60%. This statistically significant finding underscores the critical impact of relatively straightforward oral hygiene measures, challenging the prevailing notion that complex and costly interventions are required to curb hospital-acquired infections effectively.

From a mechanistic perspective, the reduction in NV-HAP risk can be understood through the microbiological interplay in the oropharyngeal environment. NV-HAP often originates from the aspiration of oral or pharyngeal secretions harboring pathogenic bacteria into the lower respiratory tract. In hospitalized patients, particularly those with limited mobility or compromised swallowing reflexes, inadequate clearance of oral secretions allows colonization by opportunistic pathogens, facilitating infection. By systematically reducing pathogenic bacteria through enhanced oral hygiene, the microbial burden in the mouth diminishes, decreasing the likelihood of aspiration pneumonia.

Professor Brett Mitchell, the study’s lead author and a prominent expert in infection prevention based at Avondale University, Australia, emphasized the transformative implications of these findings. He noted that previous barriers to effective oral hygiene implementation—such as limited product availability, low perceived importance among clinical staff, and competing priorities—were effectively overcome through targeted education and resource provision. This holistic approach not only bolstered oral care delivery but also fostered patient engagement, a vital component in sustaining care improvements.

The HAPPEN study results coincide with emerging awareness in clinical guidelines about the role of oral care in NV-HAP prevention. However, until now, empirical evidence from rigorous randomized clinical trials was lacking, limiting widespread adoption. With this study providing compelling, high-quality data, hospital systems worldwide may be prompted to reevaluate their infection control policies, incorporating structured oral hygiene programs as standard practice.

Despite these promising outcomes, Professor Mitchell stressed the importance of translating these findings into routine clinical workflows. Identifying optimal strategies for sustained implementation, including integration with electronic health records, continuous staff education, and patient-centered approaches, will be critical. The preservation of consistent adherence over time promises not only reduced NV-HAP rates but also broader benefits, such as shorter hospital stays, reduced antibiotic use, and diminished healthcare costs.

This trial also opens avenues for further research into the microbiome dynamics of the oral cavity in hospitalized patients and the development of novel antiseptic agents or delivery systems that could amplify the prophylactic effect. Longitudinal studies tracking patient outcomes beyond discharge and examining impacts on antimicrobial resistance patterns will complement the immediate findings of the HAPPEN study.

In conclusion, the HAPPEN trial signifies a paradigm shift in infection control by demonstrating that simple, low-cost, and scalable oral hygiene interventions can dramatically lower NV-HAP risk. This approach empowers healthcare providers to take proactive steps against a pervasive and perilous hospital-acquired infection, potentially saving thousands of lives annually. As the medical community absorbs these findings, the emphasis on oral care may well become a cornerstone of patient safety protocols in hospitals around the world.

Subject of Research: Prevention of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) through improved oral hygiene in hospitalized patients.

Article Title: Landmark Trial Demonstrates 60% Reduction in NV-HAP Through Enhanced Oral Care in Hospitals

News Publication Date: Monday, 20 April 2026

Web References:
– ESCMID website: www.escmid.org

References:
1. Mitchell, B., White, N., Russo, P., et al. (2026). The hospital acquired pneumonia prevention (HAPPEN) study: a multi-centre randomised controlled trial. Oral presentation. ESCMID Global 2026.
2. Pittaway, H., Grudzinska, F., Livesey, A., et al. (2024). Management of non-ventilated hospital acquired pneumonia. Clinical Infection in Practice, 21, 100350.
3. Mitchell, B. G., Russo, P. L., Cheng, A. C., et al. (2019). Strategies to reduce non-ventilator-associated hospital-acquired pneumonia: A systematic review. Infection, Disease & Health, 24(4), 229–239.

Keywords: non-ventilator-associated pneumonia, hospital-acquired infection, oral hygiene, infection prevention, clinical trial, hospital care, pneumonia risk reduction, microbial colonization, patient safety, infection control protocols

The intricate nature of airflow dynamics in enclosed hospital environments can lead to unexpected outcomes in the movement of airborne particles. Researchers aimed to investigate how mechanical ventilation and PACs influence the dispersal of aerosol particles that mimic those emitted by individuals infected with respiratory viruses, such as SARS-CoV-2 and influenza. By employing aerosol generators and particle counters, the study meticulously monitored the travel of these aerosolized particles within a typical outpatients’ clinic in central London, simulating various scenarios to assess how different configurations affected particle migration.

The experimental design allowed researchers to test numerous variables, including the positioning of ventilation and PACs, as well as the impact of physical barriers, like closed doors. Interestingly, while one might expect that increasing air circulation would result in reduced particle concentration in the air, the data revealed a more complex picture. In certain scenarios, the use of PACs led to an increase in aerosol spread by as much as 29 percent between adjacent rooms. Consequently, built-in ventilation systems sometimes resulted in aerosol migration soaring up to 5.5 times greater compared to scenarios where no ventilation was utilized.

Professor Laurence Lovat, the senior author of the study, emphasized the irony of the findings, stating that while tackling airborne viral infections in hospitals became an urgent priority during the pandemic, the complexity of airflow in these environments necessitated a nuanced approach to deploying air purification technologies. Notably, the researchers found that even in modern facilities like UCLH, established less than two decades ago, airflow behaviors remained unpredictable. In contrast, older hospitals with natural draughts could present even more convoluted airflow dynamics, further complicating infection control.

Through a series of strategic experiments, including tracking aerosol particle movement in both open and closed environments, researchers discerned notable patterns indicative of airflow’s role in particle dispersal. For instance, when doors remained open and a PAC was activated in a waiting room, unexpectedly high concentrations of particles were detected in rooms situated farthest from the aerosol source, drawing attention to a significant aspect of airborne transmission. This situation raised legitimate questions around the placement and operation of air purification devices in medical settings, as well as their potential impacts on staff and patients.

The results indicate a critical need for a refined approach to the implementation of ventilation and air cleaning systems in hospitals. In examining how different airflow patterns interact with the physical design of clinic spaces, the research team is pushing toward an advanced understanding of how to optimally position air cleaners and ventilation to minimize the risk of airborne infections, highlighting the insufficiency of blanket policies on air quality improvements.

Dr. Jacob Salmonsmith, the first author of the study, elaborated on the counterintuitive outcomes seen in certain experiments. Traditional views suggest that improving air turnover within a room would diminish the risk of airborne viral transmission; however, the study indicated that larger PACs, due to their design and airflow characteristics, could inadvertently promote the propagation of unfiltered aerosol particles. This finding underscores the intricate interplay between air currents produced by ventilation systems, the movement of people, and the effects of closed or opened doors, all of which can influence the realm of particle spread in unexpected ways.

Considering these complexities, innovative approaches, including AI simulations of airflow patterns within medical facilities, are already being developed by the research team. This technology aims to provide a more comprehensive understanding of how various devices and their placements could alter the distribution of aerosolized particles, leading to safer hospital environments and more effective strategies for infection control.

The potential practical implications of this research extend beyond academic inquiry, as enhanced knowledge of airflow dynamics can inform governmental guidelines and regulations regarding air quality standards in healthcare settings. Ensuring that NHS standards for ventilation and infection control are not only adequate but optimized for prevailing health threats is paramount in learning from the COVID-19 pandemic experience.

Through methodical experimentation and contextual understanding of hospital environments, researchers hope to share insights that can mitigate risks of airborne infections, refining our responses and preventative strategies. The need to balance effective air purification with an awareness of the complexities of airflow dynamics may serve as a vital cornerstone for future hospital design and public health policy.

As we move forward, the lessons gleaned from this comprehensive study can empower healthcare facilities to make informed decisions regarding the deployment of technologies aimed at curtailing the spread of airborne pathogens. The goal remains not only to protect vulnerable populations but also to navigate the challenging interplay between human-made interventions and naturally occurring airflow patterns within indoor environments.

In sum, the findings from UCL and UCLH underscore a critical imperative: as we enhance our response strategies to infectious diseases, we must remain cognizant of the multifaceted and sometimes unpredictable nature of indoor air movement. By doing so, hospitals can evolve into safer environments for patients and staff alike, paving the way for healthier futures.

Subject of Research: The Influence of Mechanical Ventilation and Portable Air Cleaners Upon Aerosol Spread in a Hospital Outpatients Clinic
Article Title: The Influence of Mechanical Ventilation and Portable Air Cleaners Upon Aerosol Spread in a Hospital Outpatients Clinic
News Publication Date: January 30, 2025
Web References: DOI Link
References: Not applicable
Image Credits: Not applicable

Keywords: Airborne viruses, mechanical ventilation, portable air cleaners, aerosol spread, healthcare environments, infection control, airflow dynamics, public health.